Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Clinical trial NCT03810742 · COMPLETED

Trial details

NCT number: NCT03810742
Sponsor: PharmaEngine
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory Solid Tumors

Start date: 2019-03-05
Primary completion: 2022-05-04
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.